BioMérieux Launches BIOFIRE® SPOTFIRE® for Rapid Mycoplasma Testing

bioMérieux, a leader in in vitro diagnostics, announced the launch of the BIOFIRE® SPOTFIRE® molecular testing solution for the pharmaceutical industry. Targeting mycoplasma detection, this new system aims to enhance quality control and accelerate decision-making. Building on the BIOFIRE® FILMARRAY® platform's success, SPOTFIRE® is expected to aid biopharmaceutical manufacturers by providing quick and reliable detection of mycoplasma, a critical quality concern in the production processes.

With rapid results delivered in under an hour, SPOTFIRE® enhances operational efficiency. Its automated workflow reduces manual steps and errors, facilitating faster decisions. The modular design saves space and offers scalable capacity, compatible with existing BIOFIRE® Mycoplasma panels. bioMérieux’s solution prioritizes innovation, reliability, and compliance, reflecting its commitment to patient safety.